Resumo

MELGARES RAMOS, María de los Ángeles; PARDO LORA, Cristina; SALAZAR RODRIGUEZ, Sirce  e  SILVEIRA MELGARES, Yiliam. Behavior of malignant eyelid tumors treated at the National Institute of Oncology and Radiobiology. Rev Cubana Oftalmol [online]. 2013, vol.26, n.2, pp. 285-293. ISSN 0864-2176.

Objective: to evaluate the clinical and histopathological behavior of malignant eyelid tumors and the treatment options followed at the National Institute of Oncology and Radiobiology. Methods: a retrospective analysis of 255 patients consecutively treated from January 1995 to July 2010 was carried out. The cases were evaluated according to location of tumor, treatment modality, recurrence, relapse, complications and survival rate. The staging of each case followed the criteria of the International Union against Cancer such T1N0M0, T2N0M0, T3N0M0, T4N0M0. Results: of the total number of patients, 54.1% were males and 45.9% females with age ranging 18 to 80 years. The most frequent location was the lower eyelid (35%) and the outer border, the predominant histopathological type was basocellular carcinoma (47.8%). The treatment of choice was surgery which was performed in 198 patients. In the study group, 50.2% of the treated cases showed tumoral persistence with infiltration of surgical section borders, which received adjuvant radiant treatment. Recurrences occurred in 3.5% of cases after 3 to 5 months and relapses appeared in 7.1% of patients after the first year of the end of the initial treatment. The most common complications were poor esthetic results, reduced vision, corneal ulcers and others. Survival rate was 86.3%. Conclusions: it is necessary to implement modern and conservative treatments as alternative to surgery, which may be able to control tumor and to improve the quality of life of specific eyelid cancer cases.

Palavras-chave : eyelids; basocellular carcinoma; epidermoid carcinoma; fatty adenocarcinomas; surgery; radiotherapy.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )